ammonium-trichloro(dioxoethylene-o-o--)tellurate and Depressive-Disorder

Major depressive disorder (MDD) is a leading cause of morbidity, and the fourth leading cause of disease burden worldwide. While MDD is a treatable condition for many individuals, others suffer from treatment-resistant depression (TRD). Here, we suggest the immunomodulatory compound AS101 as novel therapeutic alternative. We previously showed in animal models that AS101 reduces anxiety-like behavior and elevates levels of the brain-derived neurotrophic factor (BDNF), a protein that has a key role in the pathophysiology of depression. To explore the potential antidepressant properties of AS101, we used the extensively characterized chronic mild stress (CMS) model, and the depressive rat line (DRL Finally, in Exp. 3 to attain insight into the mechanism we knocked down BDNF in the hippocampus, and demonstrated that the beneficial effect of AS101 was abrogated. Together with the previously established safety profile of AS101 in humans, these results may represent the first step towards the development of a novel treatment option for MDD and TRD.

Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Dentate Gyrus; Depressive Disorder; Disease Models, Animal; Drug Evaluation, Preclinical; Ethylenes; Exploratory Behavior; Gene Knockdown Techniques; Hippocampus; Immunologic Factors; Male; Motor Activity; Open Field Test; Rats; Rats, Sprague-Dawley; RNA Interference; RNA, Small Interfering; Stress, Physiological; Sucrose; Swimming